- Home
- UHG vs AKBA Comparison
UHG vs AKBA Comparison
Compare UHG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- AKBA
- Stock Information
- Founded
- UHG 2004
- AKBA 2007
- Country
- UHG United States
- AKBA United States
- Employees
- UHG N/A
- AKBA N/A
- Industry
- UHG Homebuilding
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- AKBA Health Care
- Exchange
- UHG Nasdaq
- AKBA Nasdaq
- Market Cap
- UHG 281.1M
- AKBA 336.2M
- IPO Year
- UHG N/A
- AKBA 2014
- Fundamental
- Price
- UHG $6.10
- AKBA $1.88
- Analyst Decision
- UHG
- AKBA Strong Buy
- Analyst Count
- UHG 0
- AKBA 2
- Target Price
- UHG N/A
- AKBA $5.75
- AVG Volume (30 Days)
- UHG 27.9K
- AKBA 2.4M
- Earning Date
- UHG 11-08-2024
- AKBA 11-07-2024
- Dividend Yield
- UHG N/A
- AKBA N/A
- EPS Growth
- UHG N/A
- AKBA N/A
- EPS
- UHG N/A
- AKBA N/A
- Revenue
- UHG $445,729,916.00
- AKBA $169,879,000.00
- Revenue This Year
- UHG N/A
- AKBA N/A
- Revenue Next Year
- UHG N/A
- AKBA $6.13
- P/E Ratio
- UHG N/A
- AKBA N/A
- Revenue Growth
- UHG 6.19
- AKBA N/A
- 52 Week Low
- UHG $5.09
- AKBA $0.80
- 52 Week High
- UHG $9.48
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- UHG 50.53
- AKBA 61.05
- Support Level
- UHG $5.82
- AKBA $1.75
- Resistance Level
- UHG $6.52
- AKBA $2.02
- Average True Range (ATR)
- UHG 0.48
- AKBA 0.11
- MACD
- UHG -0.02
- AKBA -0.02
- Stochastic Oscillator
- UHG 35.16
- AKBA 60.00
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.